Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

INTRODUCTION: Anaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in di...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Rubens Barros, Costa, Ricardo L.B., Talamantes, Sarah M., Kaplan, Jason B., Bhave, Manali A., Rademaker, Alfred, Miller, Corinne, Carneiro, Benedito A., Mahalingam, Devalingam, Chae, Young Kwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955140/
https://www.ncbi.nlm.nih.gov/pubmed/29774128
http://dx.doi.org/10.18632/oncotarget.25154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955140/
https://www.ncbi.nlm.nih.gov/pubmed/29774128
http://dx.doi.org/10.18632/oncotarget.25154

Ejemplares similares